and chemical genetics to validate and guide target biology and pharmacology
Our biology engine is powered by small molecule control of chimeric proteins, yielding details on the depth and duration of target modulation needed to drive pharmacology.
We use insights from INFINI-T to match target to small molecule modality and guide the optimization of leads by medicinal chemistry toward effective therapeutics for patients.
>10K covalent fragments
for ligand discovery by
scalable biochemical and in cell proteomics
Our ligand discovery engine is powered by a diverse library of covalent fragments that extends beyond cysteine and can address all ligandable amino acids.
We use protein structure and computation to optimize covalent hits into leads where the small molecule modality is matched to target biology.
Nexo Therapeutics today emerged from stealth with a $60 million Series A financing led by founding investor Versant Ventures with participation from New Enterprise Associates and Cormorant Asset Management. The financing supports Nexo’s platform that combines combines the power of covalent ligand discovery and chemical biology to unlock a pipeline of novel cancer therapies directed against previously intractable targets.
Nexo Therapeutics, a biotechnology company dedicated to the discovery and development of novel cancer therapies, and The University of Texas MD Anderson Cancer Center today announced a multi-year strategic collaboration with the goal to produce impactful new cancer therapies for patients with limited treatment options . The agreement brings together Nexo’s unique drug discovery platform with the translational research and drug development expertise of MD Anderson’s Translational Research to AdvanCe Therapeutics and Innovation in ONcology (TRACTION) platform in order to accelerate development of small-molecule therapies in Nexo’s pipeline.
11757 W. Ken Caryl Avenue
Suite F, 520
Littleton, CO 80127
65 Grove Street
Watertown, MA 02472